$AXXE Big Bounce Alert!

AXXESS PHARMA INC.
OTCPK: (AXXE)

COMPANY WEBSITE

About Us

Axxess Pharma: a focused healthcare company dedicated to providing a wide range of products to improve the lives of patients and consumers worldwide.

We believe action defines leadership.

Our 23 wholly-owned prescription and non-prescription products are targeted to improve health-related conditions including several forms of iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections, infant cradle cap, joint pain and much more. Axxess Pharma intends to market these products with affordable pricing and widespread availability. Our company will continue to tap the well of innovation to develop ever-more effective and affordable treatment options for the patients we serve, and also foster innovation in education, leadership and advocacy.

Personal passion concerning the well-being of chronic illness sufferers is a major driving force and at the heart of our company. Affordable, proven, prescription and non-prescription products are a critical component to our company Business Plan. We balance environmental impact, social contribution, and financial results. Axxess Pharma is publicly traded on the US stock exchange under the ticker symbol: AXXE.

• High-dose oral iron supplement
• Low side-effect oral iron
• Severe anemia oral iron treatment
• Oral iron with erythropoietin
• Triferex the original high-dose oral iron supplement

• Anemia and high-dose oral iron
• Vegetarians and high-dose oral iron
• Dialysis and high-dose oral iron
• High-dose oral iron vs. Intravenous iron
• Compliance issues in high-dose oral iron

• Headache remedies
• Migraine treatments
• Treatment for migraines with nausea
• Migraine medicines
• Low-cost and effective migraine treatments

• Cradle Cap remedies
• Severe dandruff treatments
• Cradle Cap shampoo
• Seborrhoeic dermatitis treatments
• Soropon Shampoo

Management

Daniel Bagi, M.D., President is a senior executive physician with 20+ year’s international experience in the medical device/pharmaceutical industry, with an emphasis on Product Development, Business Development and licensing. Expertise in product development as it pertains to clinical development for commercial use; medical affairs and clinical research, specifically oncology and gynecologic topical women’s health products. Good knowledge of international regulatory standards. Secured numerous license deals internationally, between North American pharma companies and local partners. Extensive experience presenting to financial institutions, regulatory agencies, and potential pharmaceutical partners.

Neil Mellor, Senior VP Sales, has over 25 years of pharmaceutical experience both in Canada and in Europe. Neil has worked for large companies such as Merck, GSK and Pfizer and has also worked with medium-sized pharma companies such as Solvay Pharma. Neil has spent the majority of his background in sales, marketing and business development and has been involved with over thirty products in numerous therapeutic areas. Neil brings a great deal of first-hand experience in commercializing products. In addition, during 2008 Neil was President of the Canadian Healthcare Licensing Association (CHLA) and currently serves as a CHLA Board member. From 1999 to 2004 Neil was Senior Product Manager for Pantoloc®, a proton pump inhibitor used to treat heartburn. During this time Pantoloc exceeded $200m in annual sales and was listed by IMS as the fourth largest pharmaceutical product in Canada. Prior to Solvay, Neil spent 3 years working with Pharmacia Consumer Healthcare (now Pfizer) in Sweden working in International marketing for the brand Nicorette®.

Stephen Taylor, Investor/Business Relations: CEO/Pres. of Taylor Capitol, Inc.,has provided Investor Relation services for years with a prior background in equity research and investment banking in the Wall Street area. Stephen Taylor possesses a deep network of connections in the investment community. This network ranges from retail brokers, fund managers, wealth managers, Wall Street analysts, investment bankers, private equity firms and senior level management consultants.

Partners

Axxess Pharma Inc. Signs Exclusive World-Wide License to Market and Sell TapouT Brand Vitamins & Minerals Pain Relief and Muscle Recovery Products.

TAPOUT website

TapouT is a leading mixed martial arts apparel and lifestyle brand. The company was started by founder Charles “Mask” Lewis Jr., and has since become a pioneer of the MMA movement. TapouT represents the biggest MMA superstars and fans, outfitting them in the hottest apparel for men, women and children. The TapouT lifestyle aims to inspire people to reach their goals and know that anything is possible if they “Simply Believe.”

AXXE Security Details
Share Structure
Market Value1 9,257,100 a/o Aug 29, 2014
Shares Outstanding 47,717,009 a/o Aug 12, 2014
Float Not Available
Authorized Shares 100,000,000 a/o Feb 21, 2014

• Axxess Pharma to Market Latest All-Natural TapouT Products to Over 50,000 US Military Personnel at Fort Hood, Texas on November 1, 2014Marketwired(Wed, Aug 27)
• Axxess Pharma Inc. Announces US Military (AAFES) Re-Ordering TapouT Product Line at Accelerated RateMarketwired(Thu, Aug 21)
• Axxess Pharma Reports Increased Global Sales Fueled by Aggressive Social Media Marketing, Additional Distributor Relationships and Celebrity Athlete SponsorshipsMarketwired(Tue, Aug 19)
• Axxess Pharma, Inc. Targets Celebrity Athlete Fan Base and Retail Customer Base Through Aggressive, Targeted Online Social Media CampaignMarketwired(Tue, Aug 12)
• Axxess Pharma Announces TapouT Product Line Now Approved by Australian Regulatory Authority: TGAMarketwired(Tue, Aug 5)
• AXXESS PHARMA INC. FinancialsEDGAR Online Financials(Wed, Jul 30)
• Axxess Pharma Inc. Secures $2 Million USD in Financing to Fulfill Increased Rate of Purchase OrdersMarketwired(Wed, Jul 30)
• Axxess Pharma Announces Audited Financials and S-1 Registration Statement Now Filed With SEC for Up-Listing to Over The Counter Bulletin Board (OTC: BB) Stock ExchangeMarketwired(Mon, Jul 28)
• Axxess Pharma and AllStar Health Brands to Meet Additional Distributors at World Renowned 2014 Olympia's Fitness & Performance ExpoMarketwired(Wed, Jul 23)
• Axxess Pharma Announces Financial Audits and Form S-1 to Be Filed With SEC Within One Week for Fully Reporting StatusMarketwired(Thu, Jul 17)
• Axxess Pharma Inc. Announces US Military (AAFES) Quickly Increasing Rate of Purchase Orders for TapouT Line of ProductsMarketwired(Wed, Jul 16)
• Axxess Pharma Becomes Primary Sponsor for Cole Whitt at New Hampshire Motor Speedway and Phoenix International RacewayMarketwired(Thu, Jul 10)
• Axxess Pharma Announces Strong Interest From International Distributors at the UFC Fan Expo(R) EventMarketwired(Tue, Jul 8)
• Axxess Pharma Inc. Receives Additional Purchase Order From US Military (AAFES) for TapouT Line of ProductsMarketwired(Tue, Jul 1)
• Axxess Pharma Reports VP of Business Development of ABG TapouT Reiterates AXXE Is Legal Licensee of TapouT BrandMarketwired(Thu, Jun 26)

pennystockdivas.com/ 


Follow on Twitter: twitter.com/PennyStockDivas


Follow on facebook: www.facebook.com/pennystock.divas?fref=ts

Like her facebook page: 
www.facebook.com/pages/Penny-Stock-Divas/185908631442850?ref=hl

Disclaimer: pennystockdivas.com is wholly owned by Global Innovator Relations LLC. This email and the content provided is intended for advertisement purposes only. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our e-mail list. PLEASE NOTE: Global Innovator Relations, LLC and pennystockdivas.com employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at http://pennystockdivas.com/disclaimer.php Release of Liability: Through use of this website/newsletter viewing or using you agree to hold pennystockdivas.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources, which we believe to be reliable, but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Pennystockdivas.com’s affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Pennystockdivas.com encourages readers and investors to supplement the information in these reports with independent research and other pro advice. All information on featured companies is provided by the companies profiled, or is available from public sources and pennystockdivas.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Pennystockdivas.com often receives compensation for marketing, awareness and investor relation services, which can be reviewed within our disclaimer. Pennystockdivas.com has been compensated $1500 by a non controlling third party for the release of this newsletter . Pennystock divas has been previously compensated by a non controlling third party for other services. Pennystockdivas.com, Global Innovator Relations, LLC nor any of its affiliates are not registered investment advisors or broker dealers.